Deep sector intelligence across branded pharmaceuticals, generics, biologics, contract manufacturing, clinical research, and biotech innovation — for drug companies, CROs, CDMOs, investors, and healthcare systems where regulatory precision and commercial insight are inseparable.
Brand lifecycle intelligence, physician prescribing behaviour research, KOL mapping, market access strategy, and launch readiness assessment for specialty pharmaceutical companies across regulated and semi-regulated Asian markets.
Generic entry timing intelligence, biosimilar physician acceptance research, price erosion dynamics, and competitive positioning for generic drug manufacturers competing in India, Southeast Asia, and emerging GCC markets.
CDMO capability benchmarking, client concentration risk assessment, regulatory audit intelligence, and M&A due diligence for contract pharmaceutical manufacturers and their private equity backers across South Asia.
Clinical site selection intelligence, patient recruitment feasibility, investigator landscape mapping, and competitive benchmarking for CROs and biopharma companies designing and executing clinical trials in Asia.
Biologics market sizing, biotech competitive landscape mapping, investor-ready TAM analysis, and commercial readiness assessment for biotech startups and growth-stage biologics companies targeting emerging market launches.
Consumer self-medication behaviour, OTC category demand sizing, pharmacy channel economics, and brand positioning intelligence for consumer health companies competing in India's rapidly formalising over-the-counter health market.
These are the actual questions clients bring to us. We've answered some version of each of them, multiple times, across multiple geographies.
Global pharmaceutical company launching a novel oncology biologic in India. NEO ran 60 oncologist interviews across 12 hospitals, KOL influence mapping, and payer landscape research across public and private hospital segments. Launch plan approved.
Mid-size Indian API manufacturer evaluating CDMO formulation services entry. Client procurement intent research across 20 global generics companies, capability gap benchmarking, and regulatory readiness assessment. Strategy approved.
PE fund acquiring an Indian generic pharmaceutical company. ANDA pipeline valuation verified, competitive erosion risk quantified by product, and regulatory site risk assessed through expert interviews. Three material risks surfaced.
19 years in pharmaceutical strategy and market research. Led 60+ launch intelligence, market access, and M&A mandates across branded, generic, and biotech in South Asia, Southeast Asia, and the GCC. Former IMS Health Strategy.
Specialist in specialty pharmaceutical KOL research and biologics market intelligence. 14 years of physician interview research, KOL mapping, and biologic launch readiness across India's oncology, immunology, and rare disease markets.
12 years in CDMO competitive intelligence and generic pharmaceutical M&A due diligence. Specialist in manufacturing capability benchmarking, ANDA pipeline valuation, and regulatory risk assessment across Indian and South Asian pharma manufacturers.
Choose the access level that suits your organisation. All licences include the full report, methodology appendix, and structured data tables. Post-sale analyst support included.